Saturday, 05 July 2014 08:34

Anticoagulation news items. Week commencing 30th June 2014

Anticoagulation therapy versus placebo for pulmonary hypertension

Cochrane Database of Systematic Reviews
No randomised evidence is available. The results of other studies (non-RCTs) provide only poor quality evidence of effectiveness of this intervention, and the results should be interpreted with caution. This review therefore highlights need for appropriately designed RCTs.

 

Desmoteplase fails to meet primary endpoint in Phase III study of acute ischaemic stroke

Biospace Inc.

The first of two Phase III studies of desmoteplase in the treatment of acute stroke within 3-9 hours after onset (DIAS-3) has failed to meet its primary endpoint (proportion of patients with a favourable outcome at day 90 compared to placebo; 51.3% v 49.8%, respectively).

 

European CHMP recommends approval of apixaban for treatment of DVT and PE and prevention of recurrence

European Medicines Agency

The CHMP has recommended a license extension for apixaban (Eliquis®) to include its use for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.

 

Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant Therapy: Systematic Review and Economic Analysis

Canadian Agency for Drugs and Technologies in Health
Point of care (POC) INR technologies were found to be generally precise and accurate when INR values are in commonly targeted therapeutic range. There was no significant difference in risk of hemorrhagic/thromboembolic events between POC and standard laboratory testing methods.

 

Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial

The Lancet
RCT (n=1228) found preconception-initiated low-dose aspirin not significantly linked to livebirth or pregnancy loss (PL) in women with 1/2 previous losses vs. placebo, and is thus not recommended for prevention of PL. Increased vaginal bleeding with aspirin was not linked to PL.

 

CMC Biologics announces development plans for first-in-class factor Xa inhibitor antidote Andexanet Alfa

Biospace Inc.
CMC Biologics, Inc. has entered in to a commercial supply agreement with Portola Pharmaceuticals, for the development of andexanet alfa, a potential first-in class factor Xa inhibitor antidote, for use in patients with a major bleed/who require emergency surgery.

 

Supporting local implementation of NICE guidance on use of the non Vitamin K antagonist oral anticoagulants (NOACs) in non-valvular atrial fibrillation

National Institute for Health and Care Excellence
This consensus report was developed following a workshop meeting discussing barriers to use of non-Vitamin K antagonist oral anticoagulants for reducing stroke risk in non-valvular AF and how these barriers might be overcome locally to facilitate appropriate use of the drugs.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services